Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat…
Ascletis Pharma Inc. announces that the U.S. Food and Drug Administration ("FDA") has approved to conduct a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV)…
Read More...
Read More...
